Phase I Clinical Results from FR104, a mAb Specific to CD28

Researchers led by Bernard Vanove of OSE Immunotherapeutics report in the December 7, 2016 issue of the Journal of Immunology on the first-in-human study of FR1041. OSE and collaborators at the University of Nantes and Janssen conducted a detailed phase I evaluation of safety, pharmacokinetics, pharmacodynamics and potency of FR104 in healthy volunteers.

Read More

Blood-based biomarkers show promise as an early diagnostic tool for RA-ILD

Researchers at Brigham and Women’s Hospital, Harvard Medical School demonstrate the utility of a blood-based panel for identifying Interstitial Lung Disease (ILD) in Rheumatoid Arthritis (RA) patients. The comorbidity of RA-ILD is prevalent and is associated with negative patient outcomes: ILD is the second leading cause of death in patients with RA. When combined with existing clinical risk factors, the biomarker panel (MMP7, PARC and SP-D) has considerable potential as an early diagnostic, which could improve clinical outcomes in patients with RA-ILD.

View Paper »

Urinary Biomarkers of Lupus Nephritis

Researchers at the University of Cincinnati College of Medicine, Ohio State University, and Johns Hopkins have identified several biomarkers of early kidney damage in patients suffering from lupus. Various combinations of the markers, including neutrophil gelatinase-associated lipocalin (NGAL) and monocyte chemotactic protein 1 (MCP-1), along with more traditional kidney markers, were able to accurately predict renal biopsy scores and disease outcome. Using these markers to measure clinical endpoints offers hope for noninvasive methods of monitoring the progression of lupus nephritis.

A Multi-biomarker Panel Proves Useful to Screen for Rheumatoid Arthritis

A new study in the journal Arthritis Care and Research demonstrates that the levels of 12 serum biomarkers can be measured and combined, using an algorithm, to assess a patient’s rheumatoid arthritis disease activity. Researchers found that their newly developed objective metric, the composite multi-biomarker disease activity (MBDA) score, was significantly associated with the common disease activity measurements currently in use, such as the Disease Activity Score that evaluates the inflammation of 28 joints. These data offer promise that the MBDA may be useful as a clinical tool to help physicians diagnose and monitor the progression of the disease and possibly a predictor of future joint damage.